PPL and ovarian carcinoma: Our current in vivo data in a mouse model indicates significantly enhanced expression of plakins (PPL, PLEC and EVPL) in recurrent mice xenografts that were previously reduced in size with paclitaxel treatment but underwent regrowth after stopping paclitaxel treatments, suggesting an association of plakins with chemoresistance and recurrence in ovarian cancer (Fig. 4).